AVROBIO, Inc. (AVRO) News
Filter AVRO News Items
AVRO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest AVRO News From Around the Web
Below are the latest news stories about AVROBIO INC that investors may wish to consider to help them evaluate AVRO as an investment opportunity.
Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year. |
Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?Here is how AVROBIO, Inc. (AVRO) and DaVita HealthCare (DVA) have performed compared to their sector so far this year. |
Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?Here is how AVROBIO, Inc. (AVRO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year. |
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday. |
AVROBIO to Explore Strategic AlternativesCAMBRIDGE, Mass., July 12, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. AVROBIO has made the determination to halt further development of its programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. |
AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 MillionCAMBRIDGE, Mass., June 12, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the closing of the previously announced agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for cystinosis to Novartis for $87.5 million in cash. |
AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 MillionCAMBRIDGE, Mass., May 22, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced an agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5 million in cash. AVROBIO retains full rights to its portfolio of first-in-class HSC gene therapies for Gaucher disease type 1 and type 3, Hunter syndrome and Pompe disease |
Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 MonthsAvrobio Inc (NASDAQ: AVRO) announced follow-up data demonstrating a durable treatment effect across key measures out to 36 months from a Phase 1/2 trial of an investigational gene therapy for cystinosis, dubbed AVR-RD-04. Cystinosis is characterized by the accumulation of the amino acid cystine (a building block of proteins) within cells due to deficient protein cystinosin. Excess cystine damages cells and often forms crystals that can build up and cause problems in many organs and tissues. The |
AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual MeetingCAMBRIDGE, Mass., May 18, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced follow-up data demonstrating a durable treatment effect across key measures out to 36 months from a collaborator-sponsored Phase 1/2 clinical trial1 evaluating an investigational gene therapy for the treatment of cystinosis. These data are being presented at the 26th Annual Meeting of the American Society of Gene an |
AVROBIO Reports First Quarter 2023 Financial Results and Provides Business UpdateCAMBRIDGE, Mass., May 11, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the first quarter ended March 31, 2023, and provided a business update. |